Oncotelic Therapeutics, Inc 8-K, filed Jan 6, 2020
Oncotelic Therapeutics, Inc. (OTLC)
About this 8-K
Oncotelic Therapeutics, Inc filed this 8-K on January 6, 2020, reporting on events of December 31, 2019.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM8-K
CurrentReport
Pursuantto Section 13 or 15(d) of the Securities Exchange Act of 1934
Dateof Report (Date of earliest event reported)
December31, 2019
MATEONTHERAPEUTICS, INC.
(Exactname of registrant as specified in its charter)
| Delaware | 000-21990 | 13-3679168 |
|---|---|---|
| (State or other jurisdiction<br><br> <br>of incorporation) | (Commission<br><br> <br>File Number) | (IRS Employer<br><br> <br>Identification No.) |
29397Agoura Road, Suite 107
AgouraHills, CA 91301
(Addressof principal executive offices and Zip Code)
Registrant’stelephone number, including area code
(650)635-7000
(Formername or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [ ] | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of class | Trading<br> Symbols | Name<br> of each exchange on which registered |
|---|---|---|
| N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
|---|
On December 31, 2019, Dr. Fatih Uckun informed Mateon Therapeutics, Inc. (the “Company”) of his intention to resign from his position as the Company’s Chief Medical Officer, effective January 6, 2020. The Company’s management and Board of Directors thank Dr. Uckun for his contributions over the past year and wish him success in his future endeavors.
| -2- |
| --- |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Mateon<br> Therapeutics, Inc. | ||
|---|---|---|
| Date:<br> January 6, 2020 | /s/ Vuong Trieu | |
| By: | Vuong<br> Trieu | |
| Chief<br> Executive Officer |
| -3- |
| --- |